丽珠医药(01513)拟收购中汇源所持新北江制药约0.13%的股份

智通财经
Nov 11

智通财经APP讯,丽珠医药(01513)发布公告,于2026年11月11日,本公司与中汇源订立新北江制药股份转让协议,本公司同意以现金对价约人民币385.25万元收购中汇源所持新北江制药约0.13%的股份(对应新北江制药注册资本约人民币30.36万元)。于新北江制药股份收购完成后,本公司在新北江制药的直接权益将由约90.64%增加至约90.77%。

中汇源作为新北江制药的员工持股平台,为进一步优化新北江制药股权结构,强化本公司对核心塬料药子公司的管控力度,提高经营决策效率,本公司拟收购部分中汇源所持有的新北江制药股份。本次交易是本公司优化子公司治理、深化产业布局的正常经营安排,符合本公司整体发展战略规划,符合本公司长远发展利益和全体股东的整体利益。本次交易不会导致本公司本期和未来财务状况及经营成果产生重大变化,不会对本公司日常经营产生不利影响。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10